Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, announces the successful closing of its previously announced acquisition of TELI Pharmaceuticals, Inc. (“TELI”). The transaction, which was approved by Telomir’s shareholders at the Company’s Annual Meeting held on March 23, 2026, establishes Telomir as the sole holder of the global rights of Telomir-1 (Telomir-Zn), consolidating worldwide rights under a single corporate structure.
Read the full article: Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/telomir-pharmaceuticals-completes-acquisition-of-teli-pharmaceuticals-1160674